Literature DB >> 15949564

Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines.

Mark E Law1, Kristen L Templeton, Gaspar Kitange, Justin Smith, Anjan Misra, Burt G Feuerstein, Robert B Jenkins.   

Abstract

Deletions of chromosome 1p and 19q arms are frequent genetic abnormalities in primary human gliomas and are especially common in oligodendrogliomas. However, the chromosome 1p and 19q status of many glioma cell lines has not been established. Using homozygosity mapping, fluorescence in situ hybridization (FISH), and comparative genomic hybridization to arrayed BAC (CGHa), we screened 17 glioma cell lines for chromosome 1 and 19 deletions. Sequence tagged site polymorphisms were used to evaluate the cell lines for regions of chromosome 1p and 19q homozygosity. Cell lines A172, U251, TP265, U118, SW1088, U87, SW1783, and D32 contained significant regions of 19q homozygosity. In addition, A172, U87, TP483, D37, U118, MO67, and TP265 contained significant regions of 1p homozygosity. FISH probes localized to 1p36.32 and 19q13.33 as well as CGHa were used to determine which cell lines had deletions of 1p and/or 19q. Cell lines A172, U87, TP483, TP265, H4, U251, and D37 were deleted for portions of 1p. CGHa and homozygosity mapping of these cell lines define a 700-kilobase (Kb) common deletion region that is encompassed by a larger deletion region previously mapped in sporadic gliomas. This common deletion region is localized at 1p36.31 and includes CHD5, a putative tumor suppressor gene. Cell line A172 was observed to have a deletion between 19q13.33 and 19q13.41, while U87 was observed to have a smaller deletion of 19q13.33. Cell lines A172 and U87 contain 1p and 19q deletions similar to those found in sporadic gliomas and will be useful cellular reagents for evaluating the function of putative 1p and 19q glioma tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15949564     DOI: 10.1016/j.cancergencyto.2004.11.012

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  26 in total

Review 1.  The Chd family of chromatin remodelers.

Authors:  Concetta G A Marfella; Anthony N Imbalzano
Journal:  Mutat Res       Date:  2007-01-21       Impact factor: 2.433

2.  Mathematical modeling to distinguish cell cycle arrest and cell killing in chemotherapeutic concentration response curves.

Authors:  Salaheldin S Hamed; Charles M Roth
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-04-27       Impact factor: 2.745

3.  Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.

Authors:  Gisela N Castro; Niubys Cayado-Gutiérrez; Vera L Moncalero; Patricia Lima; Rodolfo Lucero De Angelis; Victor Chávez; F Darío Cuello-Carrión; Daniel R Ciocca
Journal:  Cell Stress Chaperones       Date:  2012-07-18       Impact factor: 3.667

4.  The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.

Authors:  Venkatadri Kolla; Koumudi Naraparaju; Tiangang Zhuang; Mayumi Higashi; Sriharsha Kolla; Gerd A Blobel; Garrett M Brodeur
Journal:  Biochem J       Date:  2015-06-01       Impact factor: 3.857

Review 5.  Role of CHD5 in human cancers: 10 years later.

Authors:  Venkatadri Kolla; Tiangang Zhuang; Mayumi Higashi; Koumudi Naraparaju; Garrett M Brodeur
Journal:  Cancer Res       Date:  2014-01-13       Impact factor: 12.701

Review 6.  ATP-dependent chromatin remodeling: genetics, genomics and mechanisms.

Authors:  Diana C Hargreaves; Gerald R Crabtree
Journal:  Cell Res       Date:  2011-03-01       Impact factor: 25.617

7.  U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line.

Authors:  Michael James Clark; Nils Homer; Brian D O'Connor; Zugen Chen; Ascia Eskin; Hane Lee; Barry Merriman; Stanley F Nelson
Journal:  PLoS Genet       Date:  2010-01-29       Impact factor: 5.917

8.  Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents.

Authors:  Jeffrey Helgager; Jie Li; Irina A Lubensky; Russell Lonser; Zhengping Zhuang
Journal:  J Oncol       Date:  2010-05-04       Impact factor: 4.375

9.  Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.

Authors:  Christopher G Duncan; Patrick J Killela; Cathy A Payne; Benjamin Lampson; William C Chen; Jeff Liu; David Solomon; Todd Waldman; Aaron J Towers; Simon G Gregory; Kerrie L McDonald; Roger E McLendon; Darell D Bigner; Hai Yan
Journal:  Oncotarget       Date:  2010-08

10.  Multivalent recognition of histone tails by the PHD fingers of CHD5.

Authors:  Samuel S Oliver; Catherine A Musselman; Rajini Srinivasan; John P Svaren; Tatiana G Kutateladze; John M Denu
Journal:  Biochemistry       Date:  2012-08-08       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.